CYTOKINETICS EVP sells 3,500 shares after option exercise

CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an exercise-and-sale transaction in company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an exercise-and-sale transaction in company stock. He sold 3,500 shares of common stock in an open-market sale at $86.62 per share and exercised options to acquire 3,500 shares at $7.80 per share. Following these transactions, he directly holds 153,902 shares of common stock and 37,386 non-qualified stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,500 shares ($276K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($303K)

Approx. gross sale proceeds $303K

Approx. exercise cost $27K

Approx. pre-tax spread $276K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$86.62	$303K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 37,386 contracts (Direct); Common Stock — 153,902 shares (Direct)

Key Figures

Shares sold: 3,500 shares Sale price: $86.62 per share Options exercised: 3,500 shares +4 more

7 metrics

Shares sold 3,500 shares Open-market sale of common stock

Sale price $86.62 per share Price for 3,500 common shares sold

Options exercised 3,500 shares Non-qualified stock options converted to common

Exercise price $7.80 per share Strike price of options exercised

Common shares held 153,902 shares Direct ownership after transactions

Options remaining 37,386 options Non-qualified stock options after exercise

Net shares direction -3,500 shares transactionSummary netBuySellShares

Key Terms

open-market sale, Non-Qualified Stock Option (Right to Buy), derivative exercise/conversion, exercise price

4 terms

open-market sale financial

"transaction_action: "open-market sale" for 3,500 common shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for option transaction"

exercise price financial

"conversion_or_exercise_price: "7.8000" for non-qualified stock option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK executive Fady Ibraham Malik report?

Fady Ibraham Malik reported a combined exercise-and-sale transaction. He exercised options for 3,500 CYTK common shares at $7.80 each, then sold 3,500 shares in an open-market transaction at $86.62 per share on the same date.

How many CYTOKINETICS (CYTK) shares did the EVP of R&D sell?

The EVP of Research & Development sold 3,500 CYTOKINETICS common shares. The sale was an open-market transaction at $86.62 per share, as disclosed in the Form 4 insider trading report filed for the specified transaction date.

What options did the CYTK executive exercise in this Form 4 filing?

The executive exercised 3,500 non-qualified stock options, each with a $7.80 exercise price. These options were convertible into CYTOKINETICS common stock and were part of a grant originally exercisable beginning in March 2018 with expiration in February 2028.

What are Fady Ibraham Malik’s CYTOKINETICS holdings after the reported trades?

After the reported transactions, Fady Ibraham Malik directly holds 153,902 CYTOKINETICS common shares. He also retains 37,386 non-qualified stock options, providing additional potential future ownership if those remaining options are exercised before their expiration date.

Was the CYTK insider transaction a net sale or net purchase of shares?

The activity reflects a net sale of CYTOKINETICS shares. While the executive exercised options to acquire 3,500 shares, he also sold 3,500 shares, and the summarized data show net sell activity of 3,500 shares for this Form 4 reporting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/07/2026 - 05:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/07/2026		M		3,500	A	$7.8	157,402	D
Common Stock	07/07/2026		S		3,500	D	$86.62	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$7.8	07/07/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	37,386	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR